GSK3901961 + GSK3845097 + GSK4427296 + Cyclophosphamide + Fludarabine
Phase 1Terminated 0 watching 0 views this week๐ค Quiet
25
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms
Conditions
Neoplasms
Trial Timeline
Dec 21, 2020 โ Jun 8, 2023
NCT ID
NCT04526509About GSK3901961 + GSK3845097 + GSK4427296 + Cyclophosphamide + Fludarabine
GSK3901961 + GSK3845097 + GSK4427296 + Cyclophosphamide + Fludarabine is a phase 1 stage product being developed by Adaptimmune Therapeutics for Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT04526509. Target conditions include Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04526509 | Phase 1 | Terminated |
Competing Products
20 competing products in Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AB0024 | Gilead Sciences | Phase 1 | 32 |
| TTI-237 | Pfizer | Phase 1 | 32 |
| 852A | Pfizer | Phase 1 | 32 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| IMC-3C5 | Eli Lilly | Phase 1 | 33 |
| LY3295668 | Eli Lilly | Phase 1/2 | 41 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Fulvestrant + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| enzastaurin | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Darolutamide + LHRH agonist/antagonist | Eli Lilly | Phase 1 | 33 |
| Gemcitabine + liposomal doxorubicin | Eli Lilly | Phase 3 | 77 |
| 120 mg LY2784544 | Eli Lilly | Phase 2 | 52 |
| LY4337713 | Eli Lilly | Phase 1 | 33 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant | Eli Lilly | Phase 3 | 77 |
| VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg | Vincerx Pharma | Phase 1 | 25 |
| VIP236 (Q3W) + VIP236 (Q2W) | Vincerx Pharma | Phase 1 | 25 |
| GEMZAR + ALIMTA | Eli Lilly | Phase 3 | 77 |